La cadena de opciones muestra datos clave de las opciones de acciones de BioNexus Gene Lab a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BioNexus Gene Lab..

BioNexus Gene Lab (NASDAQ:BGLC) Bolsa, Cadena de Opciones

BioNexus Gene Lab

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

WIIM

EMPG

Empro Group shares are trading higher. The stock may be moving on continued strength following its $5.5 million IPO yesterday.

As Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) prepares to unveil its second-quarter <a href="https://www.benzinga.com/quote/DAL/earnings">earnings on July 10,</a> the aviation giant finds itself at a critical juncture, facing a potential dip in profits amid a backdrop of strategic investments and shifting market dynamics.
Analysts expect the company to report quarterly earnings at $2.03 per share, down from $2.36 per share in the year-ago period. Delta Air Lines projects to report quarterly revenue of $16.18 billion, compared to $16.66 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Delta Air Lines and Korean Air announced on May 9 that they will be purchasing minority stakes worth a combined $550 million in Canadian carrier WestJet.
With the recent buzz around Delta Air Lines, some investors may be eyeing potential gains from the company's dividends. As of now, Delta Air Lines offers an annual dividend yield of 1.50%, which is a quarterly dividend amount of 18 cents per share (75 cents a year).  
So, how can investors capitalize on its dividend yield to earn a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $401,040 or around 8,000 shares. For a more modest $100 per month or $1,200 per year, you would need $80,208 or around 1,600 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.75 in this case). So, $6,000 / $0.75 = 8,000 ($500 per month), and $1,200 / $0.75 = 1,600 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
DAL Price Action: Shares of Delta Air Lines gained 2.3% to close at $50.13 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a></li>
</ul>
Photo: kamilpetran/Shutterstock

Earnings

Long Ideas

News

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q2 Earnings

OSTX

OS Therapties shares are trading higher after the company announced it has been granted an end-of-phase 2 meeting by the FDA to review OST-HIER2.

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

Price Target

Analyst Ratings

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

JMP Securities analyst Trevor Cranston downgrades Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) from Market Outperform to Market Perform.

Downgrades

JMP Securities Downgrades Two Harbors Inv to Market Perform

MIRA

MIRA Pharmaceuticals shares are trading higher after the company reported clinical data for Mira-55. Additionally, the company announced it is making advancements regarding its SKNY acquisition.

New benchmark confirms LENSai's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data.
ImmunoPrecise Antibodies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA's patented HYFT&#xAE; technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training.

Biotech

General

ImmunoPrecise's LENSai Achieves Ability To Accurately Predict Binding On 17 Previously Unseen Antibody-Antigen Complexes, Achieving Near-Crystallography Precision Without Prior Training Data

Inovio Pharmaceuticals shares are trading lower after the company announced a $25 million public offering.

Canaccord Genuity analyst Joseph Vafi maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Buy and maintains $9 price target.

HIVE

Canaccord Genuity Maintains Buy on HIVE Digital Technologies, Maintains $9 Price Target

Jones Trading analyst Justin Walsh downgrades Theratechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) from Buy to Hold.

THTX

Jones Trading Downgrades Theratechnologies to Hold

AEBI

Aebi Schmidt shares are trading higher after making its Nasdaq debut following its merger with the Shyft Group.

<ul>
<li>High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico</li>
<li>In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated</li>
<li>Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States</li>
</ul>
BAD HOMBURG, Germany, July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration&nbsp;(HighVolumeHDF)&nbsp;access for patients in seven out of 10 centers in Mexico, by partnering with the country's Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to develop a pilot program that provides low-income patients without medical coverage in Mexico with access to hemodialysis therapies. &nbsp;
Fresenius Medical Care Mexico and CCINSHAE signed a two-year contract to enable the installation of the Fresenius Medical Care 5008S CorDiax technology in participating renal treatment centers in CCINCSHAE Centers in Mexico City (CDMX) and its metropolitan area, for a total of 150 systems in all.

FME To Extend HighVolumeHDF Access For Patients In Seven Out Of 10 Centers In Mexico, By Partnering With CCINSHAE To Develop Pilot Program Providing Low-Income Patients Without Medical Coverage In Mexico With Access To Hemodialysis Therapies

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

RedCloud Holdings plc ("RCT") ("RedCloud" or the "Company"), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase its ordinary shares, and accompanying warrants that is expected to result in approximately $13.5 million in gross &nbsp;proceeds&nbsp; &nbsp;before deducting placement agent fees and other private placement expenses.
The private placement includes an investment of $7.5M from the Company's largest current shareholder and one of its directors.
At the closing, the Company will issue to the investors an aggregate of 9,000,000 ordinary shares, along with accompanying warrants to purchase an aggregate of 18,000,000 ordinary shares, at a combined purchase price of $1.50 per ordinary share and accompanying warrants. The accompanying warrants have an exercise price of $1.50 per ordinary share and will become exercisable&nbsp;immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close on or around July 7, 2025, subject to the satisfaction of customary closing conditions.
Roth Capital Partners is acting as the exclusive placement agent for the private placement and Clear Street is acting as financial advisor.

Offerings

RedCloud Holdings Announces $13.5M Private Placement Of 9M Shares And 18M Warrants At A Combined Price Of $1.50

E2open Parent Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NASDAQ">ETWO</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/ETWO/earnings">closing bell on Thursday, July 10.</a>
Analysts expect the Addison, Texas-based company to report quarterly earnings at 4 cents per share, compared to 4 cents per share in the year-ago period. E2open projects to report quarterly revenue of $148.92 million, compared to $151.16 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 25, E2open agreed to be acquired by WiseTech Global for $3.30/share in all-cash deal following strategic review.
E2open shares gained 0.6% to close at $3.25 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/etwo/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Goldman Sachs analyst Adam Hotchkiss maintained a Sell rating and cut the price target from $2.6 to $2.3 on March 28, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Loop Capital analyst Mark Schappel maintained a Hold rating and slashed the price target from $4 to $3 on Dec. 23, 2024. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying ETWO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/etwo/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="630" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34-1024x630.png" alt="" class="wp-image-971548" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34-1024x630.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34-768x473.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03035121/image-34.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

ETWO

Top Wall Street Forecasters Revamp E2open Expectations Ahead Of Q1 Earnings

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Thursday.
Shares of Franklin Covey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) fell sharply in today's pre-market trading after the reported downbeat results for the third quarter and lowered its FY2025 sales guidance <a href="https://www.benzinga.com/quote/FC/earnings">after the closing bell on Wednesday</a>.
The company posted a quarterly loss of 11 cents per share, which missed the analyst consensus estimate of a loss of 4 cents per share. The company reported quarterly sales of $67.121 million, which missed the analyst consensus estimate of $67.491 million.
Franklin Covey shares dipped 10.1% to $21.72 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Noah Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) shares dipped 7.3% to $11.69 in pre-market trading.</li>
<li>Scage Future American Depositary Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) fell 6.3% to $5.20 in pre-market trading after jumping over 34% on Wednesday.</li>
<li>Borr Drilling Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) declined 4.7% to $2.01 in pre-market trading after the company announced a $100 million offering of approximately 50 million shares.</li>
<li>Lithium Argentina AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAR#NYSE">LAR</a>) fell 4.7% to $2.23 in pre-market trading after gaining 11% on Wednesday.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) fell 4.6% to $55.81 in pre-market trading after gaining 27% on Wednesday.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) declined 4.2% to $1.3600 in pre-market trading after falling 4% on Wednesday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

BMNR

BORR

NOAH

SCAG

Franklin Covey, Borr Drilling And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Wolfe Research analyst Bill Carcache upgrades Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) from Peer Perform to Outperform.

Upgrades

HBAN

Wolfe Research Upgrades Huntington Bancshares to Outperform

INVZ

Innoviz Regains Compliance with Nasdaq

Wolfe Research analyst Bill Carcache downgrades PNC Financial Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) from Outperform to Peer Perform.

Wolfe Research Downgrades PNC Financial Services Gr to Peer Perform

Corporate Update on SKNY Merger
MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction.
"We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth."

MIRA Pharma Advances SKNY Acquisition As SEC Clears Merger Proxy; SKNY-1 Shows 30% Weight Loss And Reverses Nicotine Cravings

Financing

Press Releases

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper

BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

BGLC

Comments

BioNexus Gene Lab

BioNexus Gene Lab (BGLC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL